{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-099251","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2024-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.036983+00:00","generated_at":"2026-06-03T21:34:06.383417+00:00","sec_items":["1.01","3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vanda adopts limited-duration rights plan; rejects Future Pak's $7.25-$7.75/share bid","bullets":["Board adopted a one-year stockholder rights plan effective April 17, 2024, triggered at 10% beneficial ownership.","Plan adopted in response to unsolicited proposals from Future Pak; latest offered $7.25–$7.75 per share.","Board unanimously rejected proposals as significantly undervaluing the company, citing robust pipeline and $6.75 cash per share.","Rights dividend payable to shareholders of record April 29, 2024; rights expire April 16, 2025.","Plan prevents open-market accumulation without a control premium; no shareholder action required."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-099251","json":"https://secwatch.observer/filing/0001193125-24-099251.json","markdown":"https://secwatch.observer/filing/0001193125-24-099251.md","text":"https://secwatch.observer/filing/0001193125-24-099251.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000119312524099251/0001193125-24-099251-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000119312524099251/d795618d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T21:34:06.383417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cabc4172b80d9b7dd6958c5c0d4c03004bfefb75","claim":"Vanda Pharmaceuticals Inc. entered into Rights Agreement with Equiniti Trust Company, LLC (effective 2024-04-17).","evidence_excerpt":"The complete terms of the Rights are set forth in a Rights Agreement (the “Rights Agreement”), dated as of April 17, 2024, between the Company and Equiniti Trust Company, LLC, a limited trust company organized under the laws of the State of New York, as rights agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000119312524099251/0001193125-24-099251-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Equiniti Trust Company, LLC"},{"label":"Effective","value":"2024-04-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}